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SObjective: To evaluate the clinical effect of the presence of a micropapillary or solid subtype on the outcomes in
lung adenocarcinoma and to determine the predictors of such a histopathologic diagnosis.
Methods:A total of 511 patients with lung adenocarcinoma3 cm were included. According to the presence of
micropapillary or solid subtypes, we classified the patients into 4 subgroups: both subtypes absent (MP/S,
n ¼ 87), either subtype present (MPþ/S, n ¼ 207 and MP/Sþ, n ¼ 196), and both present (MPþ/Sþ,
n ¼ 21) to determine the association between the micropapillary or solid subtype and survival outcome or clin-
ical and imaging conditions. Univariate and multivariate analyses were undertaken to determine the parameters,
allowing the prediction of the presence of the micropapillary or solid subtype.
Results: Overall survival (OS) and disease-free survival (DFS) differed significantly among the 4 subgroups
(P<.001 and P ¼ .004, respectively). The MP/S tumors showed better DFS than those containing either
the micropapillary or solid subtype. Patients with the micropapillary subtype had significantly worse OS than pa-
tients without the micropapillary subtype. This difference remained significant, together with stage, after adjust-
ment for gender, age, adjuvant therapy, tumor size, and solid subtype (DFS and OS, P ¼ .016 and P ¼ .002,
respectively). On multivariate analysis, greater than stage I, tumor size 2.5 cm, solid mass, and maximal stan-
dardized uptake value of 7 were independent predictors of the presence of a micropapillary or solid subtype.
Conclusions:Micropapillary and solid subtypes are common in tumors greater than stage I, with size 2.5 cm,
pure solid type, and maximal standardized uptake value of 7, which were predictors for poor DFS. The
presence of the micropapillary subtype was a single prognostic factor for OS. (J Thorac Cardiovasc Surg
2014;147:921-8)Supplemental material is available online.Earn CME credits at
http://cme.ctsnetjournals.org
With advances in the understanding of lung adenocarci-
noma (ADC), a new classification was published by the In-
ternational Association for the Study of Lung Cancer
(IASLC), American Thoracic Society (ATS), and European
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The Journal of Thoracic and Cathey defined 5 distinctive subtypes of invasive lung ADCs in
association with the prognosis, stating lepidic as favorable,
acinar and papillary as intermediate, and micropapillary
and solid as poor. In particular, micropapillary, which was
not included in the 2004 World Health Organization classi-
fication, was added, and the clinical effect of this new sub-
type is one of the academic issues.
To date, several studies have attempted to determine the
prognostic value of the histologic subtypes of the new lung
ADC classification.2-5 From these previous studies, we
hypothesized that additional work about the predictive
value of the histologic subtypes according to the IASLC/
ATS/ERS proposal,1 especially the micropapillary and solid
patterns as poor prognostic factors, would improve the clin-
ical relevance of this novel classification. In addition, clin-
ical and radiologic parameters that can allow one to suggest
the presence of a micropapillary or solid subtype would
help predict the prognosis of patients with invasive ADC
preoperatively.6 In the present study, we investigated the
effect of the presence of a micropapillary or solid pattern
on overall survival (OS) and disease-free survival (DFS)
in patients with invasive pulmonary ADC of all tumor
stages.We also performed analyses to determine the clinical
and radiologic predictors that could provide suggestions
regarding the presence of a histopathologically proven
micropapillary or solid pattern of ADC.rdiovascular Surgery c Volume 147, Number 3 921
Abbreviations and Acronyms
ADC ¼ adenocarcinoma
ATS ¼ American Thoracic Society
CI ¼ confidence interval
CT ¼ computed tomography
DFS ¼ disease-free survival
ERS ¼ European Respiratory Society
GGO ¼ ground glass opacity
IASLC ¼ International Association for the
Study of Lung Cancer
MP ¼ micropapillary
OR ¼ odds ratio
OS ¼ overall survival
PET ¼ positron emission tomography
ROC ¼ receiver operating characteristic
S ¼ solid
SUVmax ¼ maximal standardized uptake value
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The institutional review board approved the present study (approval no.
2008-10-057), and informed consent was waived for the use of the patients’
medical data.
Patients
Using an oncology database at Samsung Medical Center from
September 2003 to August 2011, we identified 621 patients with
completely resected solitary invasive lung ADC that was 3 cm. None
had a history of neoadjuvant treatment. The diagnoses were made accord-
ing to the criteria of the current World Health Organization classification
for lung cancer.7 Of the 621 patients, 68 were excluded because of
prognosis-related factors: the presence of micrometastasis at surgery in
25 and the concomitancy of other cancer in 43. Another 42 patients were
excluded because of radiology- or pathologically related factors: (1) insuf-
ficient pathologic slides for evaluation of the whole tumor (n ¼ 26); (2)
poor computed tomography (CT) image quality (n ¼ 10); and (3) limited
tumor evaluation owing to combined extensive inflammation or infarction
(n ¼ 6).
Thus, 511 patients (279 males, 232 females; median age, 61 years) were
included in the present analysis (Figure 1). The median follow-up period
was 77 months (range, 10.1-255.8). First, the patients were classified by
the most predominant subtypes as follows: 49 (10%) with lepidic-
predominant tumors, 267 (52%) with acinar-predominant tumors, 61
(12%) with papillary-predominant tumors, 107 (21%) with solid-
predominant tumors, and 27 (5%) with micropapillary-predominant
tumors. Next, we classified patients into 4 subgroups according to the pres-
ence of the micropapillary and solid subtypes: both subtypes absent
(MP/S), micropapillary subtype present and solid subtype absent
(MPþ/S), micropapillary subtype absent and solid subtype present
(MP/Sþ), and both present (MPþ/Sþ). Such subtyping was conducted
to determine the association between the micropapillary and/or solid sub-
type and OS and DFS and the clinical and radiologic findings. Of the 511
ADCs, 87 were classified as MP/S (17.0%), 207 as MPþ/S (40.5%),
196 as MP/Sþ (38.4%), and 21 as MPþ/Sþ (4.1%). Finally, to investi-
gate the clinical and radiologic parameters predicting the presence of the
micropapillary or solid subtype, we divided the patients into 2 groups:
those with tumors containing either the micropapillary or solid subtype
(n ¼ 424) and those without tumors containing either subtype (n ¼ 87).922 The Journal of Thoracic and Cardiovascular SurgClinical Assessment
The clinical information was available from the patient medical records.
We screened the data, including gender, age, tumor stage using the TNM
classification, resection type, adjuvant therapy, survival, and disease pro-
gression. OS was defined as the interval from surgery to the date of death
or final follow-up visit. DFS was defined as the interval from surgery to the
point of any definite clinical or pathologic evidence of local or distant
disease recurrence or last evaluation.
Imaging and Interpretation
The imaging characteristics of each primary lung tumor were evaluated
using chest CT and the positron emission tomography (PET) component
images of PET-CT (see Appendix E1). PET-CT and chest CT were per-
formed within the 2-week period from surgery. The imaging methods
have been described in detail in previous reports.2,8
Two radiologists (E.J. L. and H.S.H., with 5 and 7 years of experience in
chest radiology, respectively), who were unaware of the clinical informa-
tion, independently evaluated the CT scans. The CT scans were retrieved
using the Picture Archiving and Communications System (Centricity, GE
Healthcare, General Electric, Fairfield, Conn). The radiologic parameters,
including tumor size, lesion density, tumor solidity, margin status, and the
presence of spiculations or lobulations were recorded. The largest diameter
measurements were obtained manually using the Picture Archiving and
Communications System measurement electronic tool in all cases. For
measurements of lesion density, the region of interest covering each target
lesion was drawn on the axial postcontrast-enhanced scan as large as
possible (at least two thirds of the longest diameter). The mean CT attenu-
ation value with standard deviation was measured in Hounsfield units.
Tumor solidity was categorized as solid, partly solid, and ground glass
opacity (GGO). GGO on the CT scans was defined as a hazy increase in
lung density without obscuration of the pulmonary vessels. The tumor
margin was classified as well-defined or ill-defined. Spiculation or lobula-
tion was defined as a radiologic outline of the lesion showing sharp points
or smooth protrusions into the surrounding tissue, respectively.
All PET images were reviewed by an experienced nuclear medicine
physician (B.T.K., with 13 years of experience in PET-CT interpretation).
The fluorodeoxyglucose uptake of the primary cancer was quantified by
calculating the maximal standardized uptake value (SUVmax) using PET
region-of-interest analysis.
Pathologic Evaluation
Whole tumor tissue sections were obtained, and each was placed on a
slide. Comprehensive histologic subtyping was performed by 2 patholo-
gists (J.H.H. and J.Y.J., with 18 and 5 years of experience in pulmonary
pathology, respectively), together at a multiheadmicroscope, and discussed
until consensus was achieved. The tumors were divided into 6 distinctive
subtypes according to the IASLC/ATS/ERS classification scheme as (1)
lepidic, (2) acinar, (3) papillary, (4) micropapillary, (5) solid, and (6) a
variant, including mucinous (Figure E1). For each case, histologic subtyp-
ing was performed for the primary tumor in a semiquantitative manner, to
the nearest 5% level, summing to a total of 100% subtype components per
tumor. For the micropapillary and solid subtypes, we also considered the
micropapillary or solid subtype to be present when the subtype occupied
1% of the entire tumor.9 Next, the most predominant pattern in a
mixed-type ADC was defined as the histopathologic subtype that consti-
tuted the greatest percentage of the tumor. The lowest limit for the predom-
inant subtype was set at 30%, as previously described.1
Statistical Analysis
The clinical prognostic parameters of each subgroup were compared
using 1-way analysis of variance with the post hoc test of Bonferroni.
The DFS and OS were estimated using the Kaplan-Meier method, and
the log-rank test was used to evaluate the differences among the subgroups.ery c March 2014
FIGURE 1. Flow chart of patient enrollment. CT, Computed tomography; MP, micropapillary; S, solid.
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and OS and was performed using backward Cox proportional hazards
regression analysis with a step-down method. The variables with P<.10
on univariate analysis were used as the input variables for the multivariate
analysis.
Univariate and multivariate analyses were undertaken to assess the clin-
ical and imaging predictors for the presence of a micropapillary or solid
subtype. The optimal cutoff values for tumor size and SUVmaxwere calcu-
lated using receiver operating characteristic (ROC) curve analysis. The
optimal cutoff values were determined as the point closest to the upper
left hand corner of the ROC curve.
As a supplementary analysis, we constructed ROC curves, plotting the
sensitivity versus 1 minus specificity, to evaluate the differentiating perfor-
mance of multivariate logistic regressionmodels in discriminating the pres-
ence of a micropapillary or solid pattern. The area under the ROC curve, a
measure of predictive power, was calculated. The statistical analysis was
performed using the Statistical Package for Social Sciences, version 15,
statistical software for Windows (SPSS Inc, Chicago, Ill). P  .05 was
considered statistically significant.
RESULTS
Correlation of Pathologic Subgroups With Clinical
Prognostic Parameters
Reclassification of the 511 ADC specimens resulted in 87
with MP/S (17.0%), 207 with MPþ/S (40.5%), 196
with MP/Sþ (38.4%), and 21 with MPþ/Sþ (4.1%;
Table 1). A total of 20 ADCs had a mucinous component
(n ¼ 19) or fetal component (n ¼ 1); however, they were
not most predominant. The median percentage of micropa-
pillary involvement in 228 patients was 2.5% (interquartile
range, 9%; 25th percentile, 1%; 75th percentile, 10%). The
median percentage of solid involvement in 217 patients wasThe Journal of Thoracic and Ca25% (interquartile range, 15%; 25th percentile, 20%; 75th
percentile, 35%).
The 4 subgroups were significantly different in terms of
gender (P ¼ .01), tumor size (median, 27.3 mm; P<.01),
TNM stage (P<.01), necessity of adjuvant chemotherapy
(P ¼ .01), disease progression (including local recurrence
and metastasis; P ¼ .01), and death rate (P ¼ .03; Table
1). Tumors without the micropapillary or solid subtype
(MP/S) tended to be smaller, less invasive (as deter-
mined by the tumor stage), less frequently required adju-
vant chemotherapy, and less frequently resulted in
disease progression or death compared with those contain-
ing either the micropapillary or solid subtype. In addition,
female patients were more likely to have MP/S
tumors.
Survival Analyses in Association With Histologic
Subtypes
First, we performed a survival analysis according to the
‘‘most predominant subtypes,’’ as proposed by the
IASLC/ATS/ERS. DFS and OS differed significantly
among the 5 different predominant subtype tumors
(P<.001 and P¼ .042, respectively; Figure 2). The patients
with lepidic-predominant tumors had a good prognosis but
those with solid- and micropapillary-predominant tumors
had a poor prognosis.
Thus, we determined whether the presence of a micropa-
pillary or solid subtype, merely 1% of the entire tumor, can
affect the survival outcome (Figure 3, A and B). OS andrdiovascular Surgery c Volume 147, Number 3 923
TABLE 1. Clinical and prognostic characteristics of 511 ADC specimens in association with 4 pathologic subgroups
Characteristic Total MP/S (n ¼ 87) MPþ/S (n ¼ 207) MP/Sþ (n ¼ 196) MPþ/Sþ (n ¼ 21) P value
Gender (n) .01
Male 279 (55) 38 (44) 105 (52) 123 (63) 13 (62)
Female 232 (45) 49 (56) 102 (49) 73 (37) 8 (38)
Age (y) .46
Range 38-86 39-81 42-86 38-81 42-80
Median 61 61 61 61 61
Tumor size (mm) <.01
Range 7-30 9-30 7-30 8-30 14-30
Median 27.3 21.3 27.6 27.7 27.8
Stage (n) <.01
I 321 (63) 80 (92) 124 (60) 106 (54) 11 (52)
II 104 (20) 6 (7) 42 (20) 51 (26) 5 (24)
IIIA 86 (17) 1 (1) 41 (20) 39 (20) 5 (24)
pLN status (n) <.01
N0 358 (70) 81 (93) 137 (66) 129 (66) 11 (52)
N1 84 (16) 5 (7) 39 (19) 34 (17) 6 (29)
N2 69 (14) 1 (0) 31 (15) 33 (17) 4 (19)
Resection extent (n) .74
Segmentectomy 34 (7) 8 (9) 11 (5) 14 (7) 1 (5)
Lobectomy 469 (92) 77 (89) 195 (94) 177 (91) 20 (95)
Pneumonectomy 8 (1) 2 (2) 1 (1) 5 (2) 0 (0)
Most predominant histologic subtype (n) <.01
Lepidic 49 (10) 30 (36) 15 (7) 3 (1) 0 (0)
Acinar 267 (52) 52 (58) 126 (61) 76 (39) 15 (70)
Papillary 61 (12) 5 (6) 41 (20) 13 (6) 2 (10)
Solid 107 (21) 0 (0) 0 (0) 105 (54) 2 (10)
Micropapillary 27 (5) 0 (0) 25 (12) 0 (0) 2 (10)
Adjuvant chemotherapy (n) 70 (14) 2 (2) 31 (15) 33 (17) 4 (19) .01
Disease progression (n) 146 (29) 12 (14) 63 (30) 58 (30) 13 (62) .01
Local recurrence 11 (2) 1 (1) 4 (2) 3 (3) 3 (14)
Metastasis 135 (27) 11 (13) 59 (28) 55 (28) 10 (48)
Death (n) 22 (4) 3 (3) 12 (6) 4 (2) 3 (14) .03
Percentages refer to each individual characteristic, with the total 100% per group.MP/S,Tumors without micropapillary or solid subtype;MPþ/S, anymicropapillary but no
solid subtype; MP/Sþ, any solid but no micropapillary subtype; MPþ/Sþ, both micropapillary and solid subtypes; pLN, pathologic lymph node.
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SDFS differed significantly among the 4 subgroups (P<.01
for all). Those with MP/S tumors had better DFS than
those with either the micropapillary or solid subtype. In
contrast, those with MPþ/Sþ tumors had poorer OS than
the other groups. Survival analyses of the tumors with
versus without a micropapillary subtype also demonstrated
a significant difference in DFS and OS (P¼ .02 and P<.01,
respectively; Figure 3, C and D).
When we analyzed the survival rates of the patients
with tumors with and without a solid subtype, however,
no significant difference was found in OS (P ¼ .87).
Only DFS was significantly worse for patients with
tumors having a solid subtype (P< .01; Figure 3, E and
F). Therefore, we performed a subgroup analysis of OS,
focusing on the presence of the micropapillary subtype
only. In the subgroup with the micropapillary subtype,
the solid subtype played a role as a strong predictor for
determining OS. However, without the micropapillary
subtype, the solid subtype showed little influence on OS924 The Journal of Thoracic and Cardiovascular Surg(Figure E2). This implies that micropapillary subtype is
a single risk factor for predicting a poor prognosis and
that the validity of the solid subtype as a predictive factor
has not yet been proved. The solid pattern contributed to
the prognosis only when it coexisted with the micropapil-
lary subtype.
Finally, multivariate analysis verified that the tumor stage
and the presence of themicropapillary subtypewere the 2 in-
dependent factors significantly associated with OS (Table
2). We observed that patients with stage I cancer showed
greater OS rates than thosewith stage II and III (hazard ratio,
0.15; 95% confidence interval [CI], 0.03-0.84; P ¼ .03). In
addition, patients with the micropapillary subtype had lower
survival rates than those without the micropapillary subtype
(HR, 4.17; 95% CI, 1.28-13.63; P ¼ .02). However, we did
not observe a significant association between the solid sub-
type and OS (P ¼ .33). The association was also not signif-
icant for tumor size (P ¼ .08), gender (P ¼ .33), age
(P ¼ .06), or use of adjuvant chemotherapy (P ¼ .82).ery c March 2014
FIGURE 2. Kaplan-Meier survival curves for disease-free and overall survival according to the most predominant subtypes.
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Micropapillary or Solid Subtype
The univariate analyses of the clinical and imaging pa-
rameters were performed for predicting the presence of the
micropapillary or solid subtype on histopathologic examina-
tion (Table 3). Among the clinical factors, gender and tumor
stage were significantly associated (P ¼ .03, and P<.01,
respectively). Of the CT findings, large (P< .01), dense
(P ¼ .02), low standard deviation of CT attenuation
(P ¼ .01), solid (P<.01), and ill-defined (P ¼ .04) tumors
were associated with the presence of the micropapillary or
solid subtype. In addition, the SUVmax on PET scans was
significantly greater in the tumors with the micropapillary
or solid subtype than in thosewithout the subtypes (P¼ .04).
Multivariate analyses (Table 4) confirmed that greater
than stage I (odds ratio [OR], 0.09; 95% CI, 0.01-0.66;
P ¼ .02), tumor size 2.5 cm (OR, 1.12; 95% CI, 1.01-
1.24; P ¼ .02), solid mass (OR, 19.82; 95% CI, 1.97-
199.46; P ¼ .01), and SUVmax 7 (OR, 1.12; 95% CI,
1.01-1.24;P¼ .03)were independent and significant predic-
tors for the presence of the micropapillary or solid subtype.
We also performed a multivariate analysis of the predic-
tors for tumors containing the micropapillary and solid sub-
type, separately (Table E1). Tumor size of 2.5 cm (OR,
0.86; 95% CI, 0.74-0.99; P ¼ .04) and ill-defined tumor
margins (OR, 0.46; 95%CI, 0.25-0.85;P¼ .01)were signif-
icant predictors for the presence of the micropapillary sub-
type. In terms of the solid subtype, male gender (OR, 1.76;
95% CI, 1.14-2.73; P ¼ .01), SUVmax 7 (OR, 0.93;
95% CI, 0.88-0.97; P< .01), and solid mass (OR, 1.73;
95% CI, 1.07-2.82; P ¼ .03) were statistically significant
as predictive parameters.Predictive Probability of Clinical Imaging
Parameters for Micropapillary or Solid Subtype
From our findings, we investigated whether we could
accurately identify patients with either the micropapillaryThe Journal of Thoracic and Caor solid subtype by reversely combining 4 clinical imaging
predictive factors (Table E2). The 4-factor combination
(model 1) of stage 2 or greater, tumor size of2.5 cm, SUV-
max of 7, and the absence of the GGO component was
accurate in predicting the presence of the micropapillary
or solid subtype, with 34 of 34 (100%) correctly predicting
the presence of the micropapillary or solid subtype (OR,
9.73; 95% CI, 2.35-40.39; P < .01). Model 2, which
included 3 imaging parameters (tumor size, solidity, SUV-
max), was also correct in predicting the subtype in 49 of
50 (98%; OR, 6.04; 95% CI, 2.57-14.18; P< .01). The
area under the ROC curve for model 2 was 0.84, reflecting
good predictability (95%CI, 0.79-0.89;P<.01; Figure E3).DISCUSSION
The survival analyses in the present study have demon-
strated that the presence of the micropapillary subtype is a
statistically significant risk factor for poor OS and DFS.
However, the solid subtype showed limited influence on
the survival outcomes. The solid subtype played a role as
a predictor for poor OS only when coexisting with the
micropapillary subtype (Figure E2). This result is analo-
gous to that from the study by Warth and colleagues,5 in
which the prognosis of solid-predominant ADCs was
improved considerably after radiotherapy but the prognosis
of micropapillary-predominant ADCs remained poor. In
contrast, Solis and colleagues10 demonstrated that those
with tumors with any solid subtype had lower OS rates
than those with tumors without a solid subtype. In our study,
the solid and nonsolid groups included 4.3% (4 of 92) and
9.4% (11 of 148) with the micropapillary pattern, and this
could have been a compounding factor. Therefore,
regarding the role of the solid subtype as a predictor of
poor survival, additional validation studies focusing on
the micropapillary subtype are necessary.
The novel classification of lung ADC has suggested that
the pathologic evaluation can be quantified by a 5%rdiovascular Surgery c Volume 147, Number 3 925
FIGURE 3. Kaplan-Meier survival curves for (A, C, and E) disease-free and (B, D, and F) overall survival according to 4 subgroups of micropapillary (MP)
and solid (S) subtypes (A and B), presence of micropapillary subtype (C and D), and presence of solid subtype (E and F). C to F, Thin lines indicate 95%
confidence intervals of the survival curves.
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whole tumor.1 However, we defined the micropapillary or
solid subtype as positive when it occupied 1% of the
entire tumor. This was to determinewhether the micropapil-
lary or solid pattern can influence patient survival, if merely
present. According to several previous studies, the presence
of the micropapillary pattern itself is a poor prognostic fac-
tor.9,11 The present study has also shown that the presence
of 1% of the micropapillary subtype is an independent926 The Journal of Thoracic and Cardiovascular Surgsignificant factor for a poor prognosis. Considering the
clinical significance of the presence of the micropapillary
pattern itself, our attempt in the present study to predict
the solid or micropapillary subtype using only clinical and
imaging factors would have greater clinical implications.
The micropapillary subtype is well-known by its unique
growth pattern, not only in the lungs, but also in other or-
gans, such as the breast, urinary bladder, ovary, and major
salivary glands.11 These tumors with the micropapillaryery c March 2014
TABLE 2. Multivariate analyses for overall survival
Characteristic HR 95% CI P value
Gender (male vs female) 1.42 0.58-3.45 .44
Age 1.05 0.99-1.09 .06
Adjuvant chemotherapy 1.21 0.24-6.18 .82
Tumor size 1.29 0.97-1.70 .08
Stage (I vs other) 0.15 0.03-0.84 .03*
Micropapillary pattern 4.17 1.28-13.63 .02*
Solid pattern 1.79 0.55-5.81 .33
HR, Hazard ratio; CI, confidence interval. *Statistically significant at P<.05.
TABLE 4. Multivariate analyses of clinical and imaging parameters
for predicting presence of micropapillary or solid subtype
Characteristic OR 95% CI P value
Gender (male vs female) 1.49 0.83-2.66 .18
Stage (I vs other) 0.09 0.01-0.66 .02*
Tumor size (2.5 vs<2.5 cm) 1.12 1.01-1.24 .02*
Tumor solidity (solid vs other) 19.82 1.97-199.46 .01*
CT density (HU) 1.00 0.99-1.00 .60
SD of CT density 1.00 0.99-1.00 .35
Margin (well- vs ill-defined) 0.40 0.15-1.08 .07
SUVmax (7 vs<7) 1.12 1.01-1.24 .03*
OR, Odds ratio; CI, confidence interval; CT, computed tomography; HU, Hounsfield
unit; SD, standard deviation; SUVmax, maximal standardized uptake value. *Statisti-
cally significant at P<.05.
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degree of aggressiveness, manifested by a high stage at
presentation, and show massive lymph node and lympho-
vascular invasion.12 Micropapillary ADC consists of small
papillary clusters of glandular cells without a fibrovascular
core, floating in the airspaces or mucinous pool.1 According
to Miyoshi and colleagues,13 the micropapillary pattern
demonstrates disruption of the cell-to-cell adhesion
complex, which can act as a basis for its invasive spread.TABLE 3. Univariate analyses of clinical and imaging parameters for
predicting presence of micropapillary or solid subtype
Characteristic
MP þ or Sþ
(n ¼ 424)
MP and S
(n ¼ 87)
P
value
Clinical factor
Gender .03*
Male 241 (57) 38 (44)
Female 183 (43) 49 (56)
Mean age (y) 60.96 59.92 .42
Stage <.01*
I 241 (57) 80 (92)
II 98 (23) 6 (7)
III 85 (20) 1 (1)
CT findings
Mean tumor size (mm) 27.7 21.3 <.01*
Mean CT density (HU) 140.241 226.563 .02*
Mean SD of CT density (HU) 121.186 139.353 .01*
Tumor solidity <.01*
Solid 118 (28) 8 (9)
Partly solid 305 (72) 68 (78)
Not solid (GGO) 1 (0) 11 (13)
Margin .04*
Well-defined 367 (87) 81 (93)
Ill-defined 57 (13) 6 (7)
Spiculation .46
Yes 133 (31) 31 (36)
No 291 (69) 56 (64)
Lobulation .09*
Yes 273 (64) 48 (55)
No 151 (36) 39 (45)
PET findings
Mean SUVmax 8.42 3.93 <.01*
The percentages refer to each individual characteristic, with the total 100% per group.
MP, Micropapillary; S, solid; CT, computed tomography; HU, Hounsfield unit;
SD, standard deviation; GGO, ground glass opacity; PET, positron emission
tomography; SUVmax, maximal standardized uptake value. *Input variables for the
multivariate analysis at P<.10.
The Journal of Thoracic and CaVarious studies over the decades have been published on
lung ADCs with the micropapillary subtype before and after
the IASLC/ATS/ERS proposal, and these studies have also
established the micropapillary pattern as a distinct poor
prognostic marker.11,12,14-16 The multivariate analysis of
the present study has corroborated those results, proving
the micropapillary subtype is a predictor of poor survival,
independent of gender, age, adjuvant chemotherapy, and
tumor size and stage. Thus, the recommendation of the
micropapillary pattern as a new subtype of lung ADC in
the novel classification is of great relevance in terms of
patient prognosis. In addition, the micropapillary subtype
was observed in 44.6% of resected lung ADC specimens
in our institution. This subtype has been encountered
quite frequently in lung ADCs. Similar results were
reported previously by other investigators. Roh and
colleagues17 reported that the micropapillary subtype and
nodal micrometastasis were found in 16 (45.7%) and 14
(40%) of 35 lung ADC specimens, respectively.
The identification of poor prognostic histologic subtypes
using only clinical and imaging factors is of great impor-
tance for predicting patient prognosis and determining the
treatment plan for inoperable and operable patients.18 The
novel classification might influence the selection of patients
in need of adjuvant therapy; therefore, imaging biomarkers
would be of great help in determining the preoperative ther-
apeutic plan. The prediction of a poor prognostic histologic
subtype is also important for patients with unresectable lung
cancer, because their pathologic information is solely
dependent on small pieces of specimen from biopsies and
not from a resected specimen. Moreover, approximately
80% of patients with lung cancer will have unresectable
tumor at the initial presentation. The results of the multivar-
iate analysis of the present study suggested that stage
greater than I, tumor size of 2.5 cm in diameter, solid
mass without a GGO component, and SUVmax of 7
were independent and significant predictors for the presence
of the micropapillary or solid subtype.
Our study had several limitations. First, our study was a
retrospective study performed at a single institution. Ourrdiovascular Surgery c Volume 147, Number 3 927
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tion. However, we tried to include a large cohort with a
logical selection process to minimize the selection bias.
Second, the range of follow-up time after surgery was rela-
tively wide. This might have influenced patient prognosis.
Selecting a proper follow-up period is important. Third,
the tumor size was limited to 3 cm in diameter. This was
because pathologic examination of the whole mass will be
limited if the tumor is>3 cm. However, the tumor size re-
striction can also influence patient prognosis and radiologic
parameters. Fourth, we used the same data set to test the
models in the supplementary analysis, and the results might
have been overoptimistic. However, in the absence of a data
set for true external validation, it was our best option to pre-
sent the probability of the predictors. Finally, by subgroup-
ing the patients into 4 groups according to the minimal
(1%) presence of each ADC subtype, the meaning of
each subtype proportion within the tumor might have
been mitigated. However, again, the patient prognosis
does not depend solely on the histopathologic examination
findings. It should be determined by integrating the histo-
pathologic findings, tumor stage, tumor size, attenuation
value, and imaging biomarker study (eg, PET) results.
In conclusion, the present study has demonstrated that
both micropapillary and solid patterns, defined in the novel
IASLC/ATS/ERS classification, are risk factors for predict-
ing poor DFS and that the micropapillary pattern is a single
powerful prognostic factor for OS. In addition, tumor stage
greater than I, lesion size of 2.5 cm, pure solid nature
without GGO, and SUVmax of 7 were significant param-
eters for predicting the presence of a micropapillary or solid
subtype. Thus, the evaluation of these factors can allow cli-
nicians to havemore accurate indicators of prognosis preop-
eratively and, therefore, might facilitate selecting patients
in need of more aggressive therapy, although they have
low-stage disease.References
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APPENDIX E1. CT AND PET/CT ACQUISITION
Helical CT images were obtained with an 8-detector row
(LightSpeed Ultra, GE Healthcare) or 16-detector row (Light-
Speed16, GE Healthcare) CT scanner. Contrast-enhanced CT
scanning was obtained 90 seconds after the administration of
contrast material (100 mL of iopamidol, Iomeron 300, Bracco,
Milan, Italy) at a rate of 1.5 mL/s using a power injector. This
was followed by 20-mL saline flushing at a rate of 1.5 mL/s.
Contrast-enhanced CT images were obtained with the following
parameters: detector collimation, 0.625 mm; field of view,
34.5 cm; beam pitch, 1.35 or 1.375; gantry speed, 0.6 second
per rotation; 120 kVp; 150 to 200 mA; and section thickness,
1.25 mm for transverse images. All imaging data were recon-
structed using soft tissue algorithms.
Fluorodeoxyglucose PET-CT images were acquired using a
PET-CT device (Discovery LS; GE Healthcare, Milwaukee,
Wis), which consisted of a PET scanner (Advance NXi, GE
Healthcare) and an 8-section CT scanner (Light-Speed Plus, GE
Healthcare).
FIGURE E1. Representative photomicrographs of the 6 histologic patterns: A, lepidic; B, acinar; C, papillary; D, micropapillary; E, solid; and F,
mucinous (hematoxylin-eosin stain, original magnification 3 400).
FIGURE E2. Subgroup analysis stratified by micropapillary subtype on overall survival.
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FIGURE E3. Receiver operating characteristic curve of model 2 of tumor
size of 2.5 cm, maximal standard uptake value of7, and the absence of
ground glass opacity component, plotting sensitivity versus 1 specificity,
illustrating an area under the curve of 0.84. AZ, Area under the receiver
operating characteristic curve.
TABLE E1. Multivariate analyses of respective clinical and imaging
parameters for predicting presence of each micropapillary and solid
subtype
Characteristics OR 95% CI P value*
Presence of micropapillary component
Tumor size (2.5 vs<2.5 cm) 0.86 0.74-0.99 .04
Margin (well- vs ill-defined) 0.46 0.25-0.85 .01
Presence of solid component
Gender (male vs female) 1.76 1.14-2.73 .01
SUVmax (7 vs<7) 0.93 0.88-0.97 <.01
Tumor solidity (solid vs other) 1.73 1.07-2.82 .03
OR, Odds ratio; CI, confidence interval; SUVmax, maximal standardized uptake
value. *All statistically significant at P<.05.
TABLE E2. Predictivity of tumors containing micropapillary or solid subtype
Model Factors All patients* (n) Patients with MP or S subtypey (n) OR (95% CI) P value AUC (95% CI)
1 Stage 2
SUVmax 7
Size 2.5 cm
Solid without GGO component
34 34 9.73 (2.35-40.39) .002 0.945 (0.923-0.968)
2 SUVmax 7
Size 2.5 cm
Solid without GGO component
50 49 6.04 (2.57-14.18) <.001 0.841 (0.794-0.889)
3 SUVmax 7
Size 2.5 cm
131 130 1.79 (1.02-3.04) .037 0.880 (0.848-0.912)
MP,Micropapillary; S, solid; OR, odds ratio; CI, confidence interval; AUC, area under the receiver operating characteristic curve; SUVmax, maximal standardized uptake value;
GGO, ground glass opacity. *Patients who fit into each model. yPatients with micropapillary or solid pattern of total given in ‘‘All patients.’’
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